img

Global Non-oncology Biopharmaceuticals Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-oncology Biopharmaceuticals Market Research Report 2024

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.
According to Mr Accuracy reports’s new survey, global Non-oncology Biopharmaceuticals market is projected to reach US$ 531430 million in 2034, increasing from US$ 295620 million in 2022, with the CAGR of 8.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-oncology Biopharmaceuticals market research.
Key companies engaged in the Non-oncology Biopharmaceuticals industry include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-oncology Biopharmaceuticals were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-oncology Biopharmaceuticals market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-oncology Biopharmaceuticals market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Segment by Type
Biologics
Biosimilars

Segment by Application


Immunology
Endocrinology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-oncology Biopharmaceuticals report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2024-2034)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Region
2.2.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2024-2024)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2024-2034)
2.3 Non-oncology Biopharmaceuticals Market Dynamics
2.3.1 Non-oncology Biopharmaceuticals Industry Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2024-2024)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2024-2024)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2022
3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2024-2024)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2024-2034)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2024-2024)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2024-2034)
6.2 North America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2024-2024)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2024-2034)
7.2 Europe Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2024-2024)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2024-2034)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2024-2024)
8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2024-2034)
9.2 Latin America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2024-2024)
9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2024-2034)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2024-2024)
10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.2.5 Sanofi Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.4.5 Pfizer Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Detail
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.5.5 Novo Nordisk Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.6.5 Novartis Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.7.5 Merck Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.8.5 Teva Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Detail
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.9.5 Eli Lilly Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.11.5 GlaxoSmithKline Recent Development
11.12 UCB Pharma
11.12.1 UCB Pharma Company Detail
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.12.5 UCB Pharma Recent Development
11.13 Amgen
11.13.1 Amgen Company Detail
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.13.5 Amgen Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Detail
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.14.5 AbbVie Recent Development
11.15 Takeda
11.15.1 Takeda Company Detail
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.15.5 Takeda Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Detail
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.16.5 AstraZeneca Recent Development
11.17 Mylan
11.17.1 Mylan Company Detail
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.17.5 Mylan Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Detail
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.18.5 LEO Pharma Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Detail
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.20.5 Alexion Pharmaceuticals Recent Development
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Detail
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.21.5 Elusys Therapeutics Recent Development
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Detail
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.22.5 Swedish Orphan Biovitrum Recent Development
11.23 Biogen
11.23.1 Biogen Company Detail
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2024-2024)
11.23.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2024-2024) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2024-2024)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2024-2034)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2024-2024) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2024-2024)
Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2022)
Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2024-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2024-2024) & (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2024-2024)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2024-2034)
Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2024-2024) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2024-2024)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2024-2034)
Table 31. North America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2024-2024) & (US$ Million)
Table 33. North America Non-oncology Biopharmaceuticals Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 35. Europe Non-oncology Biopharmaceuticals Market Size by Country (2024-2024) & (US$ Million)
Table 36. Europe Non-oncology Biopharmaceuticals Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 38. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2024-2024) & (US$ Million)
Table 39. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 41. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2024-2024) & (US$ Million)
Table 42. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 44. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2024-2024) & (US$ Million)
Table 45. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2024-2034) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Non-oncology Biopharmaceuticals Product
Table 49. Roche Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Non-oncology Biopharmaceuticals Product
Table 54. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. Johnson & Johnson Company Detail
Table 57. Johnson & Johnson Business Overview
Table 58. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 59. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 60. Johnson & Johnson Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer Non-oncology Biopharmaceuticals Product
Table 64. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Novo Nordisk Company Detail
Table 67. Novo Nordisk Business Overview
Table 68. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 69. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 70. Novo Nordisk Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Non-oncology Biopharmaceuticals Product
Table 74. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Merck Company Detail
Table 77. Merck Business Overview
Table 78. Merck Non-oncology Biopharmaceuticals Product
Table 79. Merck Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Teva Company Detail
Table 82. Teva Business Overview
Table 83. Teva Non-oncology Biopharmaceuticals Product
Table 84. Teva Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 85. Teva Recent Development
Table 86. Eli Lilly Company Detail
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 89. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 90. Eli Lilly Recent Development
Table 91. Bristol-Myers Squibb Company Detail
Table 92. Bristol-Myers Squibb Business Overview
Table 93. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 94. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 95. Bristol-Myers Squibb Recent Development
Table 96. GlaxoSmithKline Company Detail
Table 97. GlaxoSmithKline Business Overview
Table 98. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
Table 99. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 100. GlaxoSmithKline Recent Development
Table 101. UCB Pharma Company Detail
Table 102. UCB Pharma Business Overview
Table 103. UCB Pharma Non-oncology Biopharmaceuticals Product
Table 104. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 105. UCB Pharma Recent Development
Table 106. Amgen Company Detail
Table 107. Amgen Business Overview
Table 108. Amgen Non-oncology Biopharmaceuticals Product
Table 109. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 110. Amgen Recent Development
Table 111. AbbVie Company Detail
Table 112. AbbVie Business Overview
Table 113. AbbVie Non-oncology Biopharmaceuticals Product
Table 114. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 115. AbbVie Recent Development
Table 116. Takeda Company Detail
Table 117. Takeda Business Overview
Table 118. Takeda Non-oncology Biopharmaceuticals Product
Table 119. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 120. Takeda Recent Development
Table 121. AstraZeneca Company Detail
Table 122. AstraZeneca Business Overview
Table 123. AstraZeneca Non-oncology Biopharmaceuticals Product
Table 124. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 125. AstraZeneca Recent Development
Table 126. Mylan Company Detail
Table 127. Mylan Business Overview
Table 128. Mylan Non-oncology Biopharmaceuticals Product
Table 129. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 130. Mylan Recent Development
Table 131. LEO Pharma Company Detail
Table 132. LEO Pharma Business Overview
Table 133. LEO Pharma Non-oncology Biopharmaceuticals Product
Table 134. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 135. LEO Pharma Recent Development
Table 136. Boehringer Ingelheim Company Detail
Table 137. Boehringer Ingelheim Business Overview
Table 138. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
Table 139. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 140. Boehringer Ingelheim Recent Development
Table 141. Alexion Pharmaceuticals Company Detail
Table 142. Alexion Pharmaceuticals Business Overview
Table 143. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
Table 144. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 145. Alexion Pharmaceuticals Recent Development
Table 146. Elusys Therapeutics Company Detail
Table 147. Elusys Therapeutics Business Overview
Table 148. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
Table 149. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 150. Elusys Therapeutics Recent Development
Table 151. Swedish Orphan Biovitrum Company Detail
Table 152. Swedish Orphan Biovitrum Business Overview
Table 153. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
Table 154. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 155. Swedish Orphan Biovitrum Recent Development
Table 156. Biogen Company Detail
Table 157. Biogen Business Overview
Table 158. Biogen Non-oncology Biopharmaceuticals Product
Table 159. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2024-2024) & (US$ Million)
Table 160. Biogen Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2022 VS 2034
Figure 3. Biologics Features
Figure 4. Biosimilars Features
Figure 5. Global Non-oncology Biopharmaceuticals Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2022 VS 2034
Figure 7. Immunology Case Studies
Figure 8. Endocrinology Case Studies
Figure 9. Others Case Studies
Figure 10. Non-oncology Biopharmaceuticals Report Years Considered
Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2022 VS 2034
Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2022
Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2022
Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Country (2024-2034)
Figure 19. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 20. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 21. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. Europe Non-oncology Biopharmaceuticals Market Share by Country (2024-2034)
Figure 23. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 24. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2024-2034)
Figure 31. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2024-2034)
Figure 39. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2024-2034)
Figure 43. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 44. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 46. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 47. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 48. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 49. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 50. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 51. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 52. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 53. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 56. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 57. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 58. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 59. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 60. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 61. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 62. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 64. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 65. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 66. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 67. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2024-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries